Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Melanoma 8Uveal Melanoma 3Multiple Myeloma 2Squamous Cell Carcinoma of Head and Neck 1Skin Neoplasms 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Eye Neoplasms 1

Interventions

Cyclophosphamide 77Dexamethasone 74Melphalan 65Lenalidomide 50Bortezomib 50Peripheral Blood Stem Cell Transplantation 49fludarabine phosphate 47Busulfan 46Filgrastim 39Tacrolimus 37Antilymphocyte Serum 33Radiotherapy 30Mycophenolic Acid 30Thalidomide 28fludarabine 24Methotrexate 22Whole-Body Irradiation 21Cyclosporine 21Calcium Dobesilate 21Granulocyte Colony-Stimulating Factor 18Methylprednisolone 17Etoposide 17Cord Blood Stem Cell Transplantation 14daratumumab 11Prednisone 11Carmustine 11sargramostim 10Stem Cell Transplantation 10Sirolimus 10Rituximab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoplasms, Plasma Cell × MAGEA3 protein, human × Clear all
NCT00090493 2013-06-24

Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

University of Arkansas

Phase 2/3 Completed
4 enrolled 6 charts
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡